Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Cisco who wrote (433)	11/3/1997 10:47:00 AM
From: Frank Buck	Read Replies (3) \| Respond to of 1894

Cisco, "The TracCell 2500. The Company is developing a second generation specimen pre-screening and slide mapping product, the TracCell 2500, to further automate the mapping process. The TracCell 2500, if sucessfully developed, will eliminate not only empty space, debris and other material eliminated by the TracCell 2000, but will also eliminate certain normal cellular material. The Company believes, based on preliminary studies it has conducted, that the technology embodied in the TracCell 2500 may be capable of further reducing the portion of the specimen required to be reviewed by the cytotechnologist. Further testing and development and resources are necessary to determine whether a commercially viable TracCell 2500 instrument can be developed. The Company's proposed automated pre-screening, specimen mapping workstation, the TracCell 2500, if developed, may not be sold in the United States unless and until the Company has obtained FDA marketing clearance, either through a 501(k) Notification or a PMA." Information obtained from the U.S. Securities and Exchange Commision Form 10-KSB Annual Report Under Section 13 Or 15 (d) of The Securities Exchange Act of 1934 for the fiscal year ended December 31, 1996. The above info is obviously dated, yet I believe the function of the new TracCell 2500 is adequately characterized. It is as previously mentioned a "second generation" cytopathology image analyzing device that maximizes scan time by looking at relevant cellular material. Cisco, perhaps it would be good timing if investors were updated by the company on the progress of the TracCell 2500. Are you up to posting an eMail to Investor Relations (I.R.)for a progress report? It seems that I have used up my "three wishes" with the I.R. "Genie", and have not received a response to my last eMail to them. There is no reason to believe I will do any better with this concern. Perhaps you can also mention that you are representing this stock-group and the response from them will serve as a "Group Answer" to a very pertinent concern of S-H-A-R-E-H-O-L-D-E-R-S of AccuMed International, Inc. Would any other shareholders, or potential shareholders like the Company to respond to this question? If so, please respond with a brief post. Perhaps the IR people are even monitoring this thread (highly-likely) and will observe that we are interested in more communications from them to keep us abreast of new and ongoing developments. Isn't that worth a few seconds of your time? After all, if you read the above post and got to here you are interested! Frank